Physician profile
Jay Kahng
NPI 1477752038
$3,479.37
in general payments reported to CMS, 2019-2025
34 companies · $852 in 2025
The $852 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $697 · 2020: $792 · 2021: $399 · 2022: $231 · 2023: $185 · 2024: $322 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,359.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $531.85 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $512.42 | 2019-2025 | |
| Amgen INC. | $382.23 | 2019-2025 | Evenity |
| Pfizer INC. | $288.47 | 2019-2025 | |
| Lilly USA, LLC | $237.71 | 2020-2025 | Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $205.07 | 2020-2023 | Eliquis |
| Abbott Laboratories | $152.17 | 2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $110.03 | 2019-2025 | Breztri, Farxiga |
| Astellas Pharma US INC | $104.10 | 2019-2021 | |
| Ibsa Pharma INC. | $90.81 | 2020-2025 | Tirosint, Licart, Tirosint |
| Glaxosmithkline, LLC. | $86.08 | 2019-2025 | Arexvy, Shingrix, Flulaval Quadrivalent |
| Amarin Pharma, INC. | $82.96 | 2019-2020 | |
| Boston Scientific Corporation | $67.65 | 2022-2023 | Superion Indirect Decompression System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.07 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $54.25 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $40.42 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $39.36 | 2019 | |
| Vertiflex, INC. | $36.16 | 2019 | |
| Merck Sharp & Dohme LLC | $35.95 | 2019 | |
| Exact Sciences Corporation | $34.25 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $30.66 | 2025 | Gemtesa |
| Tersera Therapeutics LLC | $29.43 | 2019 | |
| Bsn Medical INC | $26.32 | 2019 | |
| Alnylam Pharmaceuticals INC. | $24.87 | 2025 | Amvuttra |
| Otsuka America Pharmaceutical, INC. | $24.83 | 2019 | |
| Metuchen Pharmaceuticals | $24.72 | 2019 | |
| Allergan, INC. | $24.66 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.46 | 2019 | |
| Scilex Pharmaceuticals INC. | $22.42 | 2019 | |
| Almatica Pharma LLC | $22.02 | 2024 | Loreev Xr |
| Vyera Pharmaceuticals, LLC | $21.81 | 2020 | |
| Medtronic Vascular, INC. | $18.36 | 2020 | |
| Medtronic, INC. | $17.50 | 2021 | |
| Genentech USA, INC. | $15.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Kahng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.